1Sanchcza JE, Sacnza NG, Rinconb MR, et al. Susceptibility of helicobacter pylori to mupirocin, oxzzolidinones, quinupristin/ dalfopristin and new quinolones. J Antimicrobial Chemother, 2000, 46:283-385.
2Mendonca S, Ecclissato C, Sartori MS, et al. Prevalence of helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter, 2000,5:79-83.
3Megraud F. Epidemiology and mechanism of antibiotic resistance in helicobacter pylori. Gastroenterology, 1998,115:1278-1282.
4Chaves S, Gadanho M, Tenreiro R. Assessment of metronidazole susceptibility in helicobacter pylori: Statistical validation and error rate analysis of breakpoints determined by the disk diffusion test. J Clin Microbiol, 1999,37:1628-1631.
5James H, Jorgensen. Selection criteria for an antimicrobial susceptibility test system. J Clin Microbiol,1993,11:2841-2844.
5NIH Consensus Conference. Helicobacterpylori in peptic uleer disease. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease[J]. JAMA. 1994,272( 1 ) : 65-69.
6MEGRAND F. H. pylori antibiotic resistence: prevalence, importance, and advances in testing[J]. Gut,2004,53(9) :1374-1384.
7De FRANCESCO V, MARGIOTTA M, ZULLO A, et al. Prevanlence of primary clarithromycin resistance in Helicobacterpylori strains over a 15 year period in Italy [ J ]. J Antimicrob Chemother, 2007, 59 ( 4 ) : 783-785.
8GISBERT J P,GISBERT J L,MARCOS S,et al. Third line rescue therapy with levofloxa is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failure [ J ]. Aliment Pharmacol Ther, 2006,24:1469-1474.
